Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Completed 93Terminated 23Recruiting 12Unknown 9Withdrawn 8Active not recruiting 7Not yet recruiting 3Suspended 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2

Conditions

Glioblastoma 2Colorectal Neoplasms 2Neuroma, Acoustic 1Neuroma 1Neurilemmoma 1Neoplasms 1Microsatellite-stable Colorectal Cancer 1Meningioma 1Carcinoma, Hepatocellular 1Brain Neoplasms 1Astrocytoma 1

Interventions

Specimen Handling 2Magnetic Resonance Spectroscopy 2Bevacizumab 2relatlimab 1aldesleukin 1TPI-287 1Surgical Procedures, Operative 1Radiotherapy, Intensity-Modulated 1Radiosurgery 1Nivolumab 1Niacinamide 1Niacin 1Metformin 1Lomustine 1Immunoglobulin G 1Disulfides 1Diet, Ketogenic 1Craniotomy 1Carboplatin 1Biopsy 1Biological Specimen Banks 1ACT001 13-aminopyridine-2-carboxaldehyde thiosemicarbazone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Suspended × Glioblastoma × Bevacizumab × Clear all
NCT01386710 2026-06-01

Repeated Super-selective Intraarterial Cerebral Infusion Of Bevacizumab Plus Carboplatin For Treatment Of Relapsed/Refractory GBM And Anaplastic Astrocytoma

Northwell Health

Phase 1/2 Suspended
54 enrolled
CNS

Astrocytoma, Glioblastoma, Neoplasms

NCT01933815 2023-02-22

Dose-Escalation Study of TPI 287 + Avastin Followed by Randomized Study of the Same Versus Avastin for Glioblastoma

Cortice Biosciences, Inc.

Phase 1/2 Suspended
92 enrolled
CNS

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡